Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
12 2022
Historique:
pubmed: 17 8 2022
medline: 23 11 2022
entrez: 16 8 2022
Statut: ppublish

Résumé

Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. To compare diagnostic performances of two different data-driven SPMS definitions. Data-driven SPMS definitions based on a version of Lorscheider's algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist's definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). A cohort of 10,240 MS patients with ⩾5 years of follow-up was extracted from the Italian MS Registry; 880 (8.5%) patients were classified as SPMS according to the neurologist definition, 1806 (17.6%) applying the DDA and 1134 (11.0%) with the EXPAND definition. The DDA showed greater discrimination power (AUC: 0.8 vs 0.6) and a higher sensitivity (77.1% vs 38.0%) than the EXPAND definition, with similar specificity (88.0% vs 91.5%). PPV and NPV were higher using the DDA than considering EXPAND definition (37.5% vs 29.5%; 97.6% vs 94.0%). Data-driven definitions demonstrated greater ability to capture SP transition than neurologist's definition and the global accuracy of DDA seems to be higher than the EXPAND definition.

Sections du résumé

BACKGROUND
Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available.
OBJECTIVES
To compare diagnostic performances of two different data-driven SPMS definitions.
METHODS
Data-driven SPMS definitions based on a version of Lorscheider's algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist's definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC).
RESULTS
A cohort of 10,240 MS patients with ⩾5 years of follow-up was extracted from the Italian MS Registry; 880 (8.5%) patients were classified as SPMS according to the neurologist definition, 1806 (17.6%) applying the DDA and 1134 (11.0%) with the EXPAND definition. The DDA showed greater discrimination power (AUC: 0.8 vs 0.6) and a higher sensitivity (77.1% vs 38.0%) than the EXPAND definition, with similar specificity (88.0% vs 91.5%). PPV and NPV were higher using the DDA than considering EXPAND definition (37.5% vs 29.5%; 97.6% vs 94.0%).
CONCLUSION
Data-driven definitions demonstrated greater ability to capture SP transition than neurologist's definition and the global accuracy of DDA seems to be higher than the EXPAND definition.

Identifiants

pubmed: 35971322
doi: 10.1177/13524585221114007
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2243-2252

Auteurs

Pietro Iaffaldano (P)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.

Giuseppe Lucisano (G)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy/Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

Tommaso Guerra (T)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.

Francesco Patti (F)

Dipartimento di Scienze Mediche e Chirurgiche e Tecnologie Avanzate, GF Ingrassia, Sez. Neuroscienze, Centro Sclerosi Multipla, Università di Catania, Catania, Italy.

Marco Onofrj (M)

Centro Sclerosi Multipla, Clinica Neurologica, Policlinico SS Annunziata, Università 'G. d'Annunzio', Chieti-Pescara, Italy.

Vincenzo Brescia Morra (V)

Multiple Sclerosis Clinical Care and Research Center, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Napoli, Italy.

Mauro Zaffaroni (M)

Multiple Sclerosis Center, Hospital of Gallarate, ASST della Valle Olona, Gallarate, Italy.

Carlo Pozzilli (C)

Multiple Sclerosis Center, Sant' Andrea Hospital, Department of Human Neuroscience, Sapienza University, Rome, Italy.

Eleonora Cocco (E)

Department Medical Science and Public health, University of Cagliari, Cagliari, Italy/Centro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy.

Patrizia Sola (P)

Neurology Unit, Department of Neurosciences, University of Modena and Reggio Emilia, Nuovo Ospedale Civile S. Agostino/Estense, Modena, Italy.

Giuseppe Salemi (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Matilde Inglese (M)

Dipartimento Di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno - Infantili (DINOGMI), Universita' di Genova, Genova, Italy/Ospedale Policlinico San Martino, IRCCS, Genova, Italy.

Roberto Bergamaschi (R)

IRCCS Mondino Foundation, Pavia, Italy.

Claudio Gasperini (C)

Centro Sclerosi Multipla, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy.

Antonella Conte (A)

Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy/IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy.

Marco Salvetti (M)

IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy/Centro Neurologico Terapie Sperimentali (CENTERS), Sapienza Universita' Di Roma, Azienda Ospedaliera Sant' Andrea, Rome, Italy.

Giacomo Lus (G)

Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.

Giorgia Teresa Maniscalco (GT)

Neurology and Stroke Unit, MS Center, 'A. Cardarelli Hospital', Naples, Italy.

Rocco Totaro (R)

Centro Malattie Demielinizzanti, Clinica Neurologica, Ospedale San Salvatore, L'Aquila, Italy.

Marika Vianello (M)

MS Unit, O.U. Neurology 'Ca' Foncello' Hospital, Treviso, Italy.

Franco Granella (F)

Unit of Neurosciences, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Elisabetta Ferraro (E)

Centro SM, PO San Filippo Neri, ASL Roma 1, Roma, Italy.

Umberto Aguglia (U)

Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.

Maurizia Gatto (M)

Centro Malattie Demielinizzanti, Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, Italy.

Francesca Sangalli (F)

Neurology, Neurorehabilitation and Neuroimaging Research Units, Neurophysiology Service, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Vita-Salute San Raffaele University, Milan, Italy.

Clara Grazia Chisari (CG)

Dipartimento di Scienze Mediche e Chirurgiche e Tecnologie Avanzate, GF Ingrassia, Sez. Neuroscienze, Centro Sclerosi Multipla, Università di Catania, Catania, Italy.

Giovanna De Luca (G)

Centro Sclerosi Multipla, Clinica Neurologica, Policlinico SS Annunziata, Università 'G. d'Annunzio', Chieti-Pescara, Italy.

Antonio Carotenuto (A)

Multiple Sclerosis Clinical Care and Research Center, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Napoli, Italy.

Damiano Baroncini (D)

Multiple Sclerosis Center, Hospital of Gallarate, ASST della Valle Olona, Gallarate, Italy.

Delia Colombo (D)

Novartis Italia, Origgio, Lombardia, Italy.

Mihaela Nica (M)

Novartis Italia, Origgio, Lombardia, Italy.

Damiano Paolicelli (D)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.

Giancarlo Comi (G)

Università Vita Salute San Raffaele, Milano, Italy/Casa di Cura del Policlinico, Milano, Italy.

Massimo Filippi (M)

Neurology, Neurorehabilitation and Neuroimaging Research Units, Neurophysiology Service, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Vita-Salute San Raffaele University, Milan, Italy.

Maria Pia Amato (MP)

Department of NEUROFARBA, University of Florence, Florence, Italy/IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.

Maria Trojano (M)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro' Bari, Piazza G. Cesare, 11, 70124 Bari, Italy.
Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH